Registration Statement for Proposed Initial Public Offering

IRadimed Corporation Files Registration Statement for Proposed Initial Public Offering

IRADIMED CORPORATION, the leading provider of non–magnetic intravenous (IV) infusion pump systems that are safe for use during magnetic resonance imaging (MRI) procedures, announced today that it has publicly filed a registration statement on Form S–1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not been determined.

Roth Capital Partners, LLC will act as sole book-running manager for the offering and Monarch Capital Group, LLC will act as co-manager.

This offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, California 92660, Attention: Equity Capital Markets, Phone (800) 678-9147 / Fax (949) 720-7227, Email: rothecm@roth.com.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About IRadimed
IRADIMED CORPORATION is the leading provider of non-magnetic IV infusion pump systems that are safe for use during MRI procedures. Electromechanical medical devices and pumps contain magnetic and electronic parts which generate radio frequency (RF) noise, create interference and are dangerous to operate in the presence of the powerful magnet which drives an MRI. The company's MRidium™ (3850/3860+) IV pump systems have been designed with non-ferrous parts, ceramic ultrasonic motors, non–magnetic mobile stand and other special features in order to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures.
Our pump solution provides a seamless approach to providing IV fluids before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants must generally be sedated in order to remain immobile during an MRI scan.

For more information please visit www.iradimed.com.
MRidium is a trademark of IRADIMED CORPORATION.

Kevin Jirka